Kalaitzopoulos Dimitrios Rafail

OBGYN consultant, MD, MSc, PhD 🇨🇭interested in Endometriosis and Reproductive surgery, Editorial Board Member BMC Women’s Health

[WES @WorldEndoSoc]

WESINAR: Discover key insights and themes from ESHRE 2025,.
23 Feb 2026 | 10:00am PST | 7:00pm CET
Moderator: Dimitrios Kalaitzopoulos
Speakers: Connie Rees, Anna Stepniewska, Laura Benaglia

👉 Register: https://t.co/1JykFVZ1FR
#WESinar #Endometriosis
@DKalaitzopoulos

[Sara @Saara_riibeiro]

Summary of que 4⃣ moderated by @DKalaitzopoulos
#ESHREjc

[Kalaitzopoulos Dimitrios Rafail @DKalaitzopoulos]

@juanjo_fraire @catiamalinina @Kristensen8511 @OmarRawi89 @ESHRE @juliauraji @AttilioDGM7 @GLiperis @Saara_riibeiro @NoemiSalme30386 I believe that, from a design perspective, it should not be difficult to conduct a retrospective clinical study examining the effect of paracetamol exposure during ovarian stimulation or embryo transfer, in order to obtain clinical evidence.

[Kalaitzopoulos Dimitrios Rafail @DKalaitzopoulos]

@GLiperis @ESHRE @OmarRawi89 @juanjo_fraire @NoemiSalme30386 @juliauraji @AttilioDGM7 @FabrizzioHorta I totally agree with you @GLiperis. The problem is that the alternatives do not appear to be less harmful than paracetamol. I think the main rule for paracetamole should be "use the lowest effective dose in the shorter time" and for sure not prophylactic #ESHREjc

[Kalaitzopoulos Dimitrios Rafail @DKalaitzopoulos]

Q4: #ESHREjc Until prospective data arrive, what’s a proportionate counseling message for TTC/IVF patients needing analgesia, what alternatives, what timing advice, and how to avoid over-restriction that drives unsafe NSAID substitution? @ESHRE

[George Liperis @GLiperis]

Over the next 24h will be engaging in discussion for a very common medication and its effect in embryological outcomes #ESHREjc 👇🏻

[Attilio Anastasi @AttilioDGM7]

🚨Q1 #ESHREjc The study finds that APAP delays cleavage-stage divisions, while blastocysts keep total cells but show reduced ICM and DNA synthesis. What do these stage-specific vulnerabilities imply for implantation and embryo competence?
@ESHRE

[Omar Ammar @OmarRawi89]

1/ This #ESHREjc we are discussing how a common analgesic Acetaminophen (APAP) may interfere with pre-implantation embryo development.

Study in focus: https://t.co/06gl7eXX2t

A tweetorial to get you up and ready for tomorrow.

#ESHREjc @ESHRE

[Omar Ammar @OmarRawi89]

🚨 Could a common painkiller disrupt the earliest stages of human embryo development?

Join us for the next #ESHREjc
🗓️ 28–29 November
⏰ 17:00 CET start
📍 on @ESHRE

🔗 https://t.co/06gl7eYuS1

🌟 @juliauraji, Thanos Papathanasiou & David Kristensen

[Kalaitzopoulos Dimitrios Rafail @DKalaitzopoulos]

Q3 on diagnostic pitfalls in adenomyosis and clinical outcomes in subtypes of adenomyosis #eshrejc
By @GLiperis

[George Liperis @GLiperis]

Q3: What are the main diagnostic pitfalls in adenomyosis? How do clinical outcomes differ in subtypes of adenomyosis? Should we define specific criteria to identify those women at higher risk? #ESHREjc @CatenaUrsula
@AlexQuaas

[Kalaitzopoulos Dimitrios Rafail @DKalaitzopoulos]

Q4 on “ideal” setting of IVF
#eshrejc
By @NoemiSalme30386

[Noemi Salmeri @NoemiSalme30386]

Q4: Moving into the “ideal” setting of IVF.

✨LBR after multiple ET reach 60–70% in women <35 years….
🔎to what extent can the remaining failure be explained by uterine factors? could this account for the entire 30–40%? Or are we missing something else? #ESHREjc

[Kalaitzopoulos Dimitrios Rafail @DKalaitzopoulos]

Q2 on the role of diagnostic criteria of uterine anomalies
By @AttilioDGM7

[Attilio Anastasi @AttilioDGM7]

🚨Q2:
Prevalence of uterine anomalies (e.g. septate uterus) shifts a lot by criteria (ESHRE/ESGE vs ASRM vs CUME).
👉🏼How does this shape practice over/under-diagnosis, over/under-treatment and interpretation of treatment outcomes?
#ESHREJC

[Kalaitzopoulos Dimitrios Rafail @DKalaitzopoulos]

Q1 on control group for the role of uterine factor in RPL #eshrejc
By @juanjo_fraire

[Juanjo Fraire-Zamora @juanjo_fraire]

Q1: To demonstrate a causal role of the uterine factor on RPL, a control group of 👭is needed with
-previous fertility
-no previous abortions
-with a 3D transv US
Is this a feasible endevour? Can causality be inferred even if diagnostic guidelines are heterogeneous? #ESHREjc

[ESHRE @ESHRE]

Many thanks to all participants 🙌 and to @DKalaitzopoulos and his team for leading this great edition of the #ESHREjc

[Alexander Quaas @AlexQuaas]

@GLiperis @ESHRE @CatenaUrsula Adenomyosis is a “shades of gray” rather than “black and white” condition so it is challenging to establish association vs causation and clinical relevance.

[Ursula Catena @CatenaUrsula]

@GLiperis @AlexQuaas Should we define high-risk criteria?
Yes — combining:
Quantitative JZ metrics.
Number of MUSA features (≥2 direct signs).
Clinical phenotype (primary RPL, multiple losses).
This could identify women most likely to benefit from early interventions or closer monitoring.

[Kalaitzopoulos Dimitrios Rafail @DKalaitzopoulos]

@NoemiSalme30386 According to this systematic review the prevalence of uterine factor infertility varies between 2.1 to 16.7%🤔

Studies are extremely heterogeneous

More questions less answers

#Eshrejc
https://t.co/4ZZhAv2HoM

[Noemi Salmeri @NoemiSalme30386]

Q4: Moving into the “ideal” setting of IVF.

✨LBR after multiple ET reach 60–70% in women <35 years….
🔎to what extent can the remaining failure be explained by uterine factors? could this account for the entire 30–40%? Or are we missing something else? #ESHREjc

[Kalaitzopoulos Dimitrios Rafail @DKalaitzopoulos]

@GLiperis @CatenaUrsula @AlexQuaas Usually Adenomyosis also co-exists with other entities.

https://t.co/a5Y1NB7klB
#eshrejc

@AlexQuaas

[Kalaitzopoulos Dimitrios Rafail @DKalaitzopoulos]

@GLiperis @CatenaUrsula @AlexQuaas Not every Uterus with Adenomyosis is the same
This is also the reason for high heterogeneity between Studies on Adenomyosis associated infertility.

A classification is needed!